Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Safety, Radiological and Patient Reported Outcomes of i-FACTOR+ Matrix Bone Graft Device - A Canadian, Multicenter, Post-Market Clinical Investigation
- Conditions
- Degenerative Disc Disease
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- CeraPedics, Inc
- Target Recruit Count
- 300
- Registration Number
- NCT05144126
P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation
- Conditions
- Degenerative Disc Disease
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- CeraPedics, Inc
- Target Recruit Count
- 290
- Registration Number
- NCT03438747
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸Keck School of Medicine USC, Los Angeles, California, United States
An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation
- Conditions
- Intervertebral Disk Degeneration
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- CeraPedics, Inc
- Target Recruit Count
- 319
- Registration Number
- NCT00310440
- Locations
- 🇺🇸
Department of Neurological Surgery UCSF Spine Center, San Francisco, California, United States
🇺🇸Spine Education Research Institute, Thornton, Colorado, United States
🇺🇸Sarasota Memorial Hospital, Sarasota, Florida, United States
News
FDA Approves First Bone Growth Accelerator for Spinal Fusion Surgery
Cerapedics received FDA premarket approval for PearlMatrix P-15 Peptide Enhanced Bone Graft, the first proven bone growth accelerator for lumbar fusion procedures.